![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Shattuck Labs Inc | NASDAQ:STTK | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.01 | -0.23% | 4.42 | 4.41 | 4.43 | 4.59 | 4.37 | 4.54 | 114,961 | 20:57:13 |
Presentation Details
Title: Bispecific gamma delta T cell engagers containing butyrophilin 2A1/3A1 heterodimeric fusion protein efficiently activate Vg9Vd2 T cells and promote tumor cell killingPresenter: Dr. Anne Lai, Ph.D., Principal Scientist, ShattuckSession: Immunology - Immunomodulatory Agents and Interventions 2 Date/Time: Tuesday, April 12, 2022, 1:30 p.m. to 5:00 p.m. ETLocation: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 37Abstract Number: 3514
Title: LIGHT (TNFSF14) costimulation with TIGIT blockade broadens the activity of checkpoint inhibitors (CPIs) into CPI refractory and resistant tumors through targeted myeloid cell and effector lymphocyte activationPresenters: Dr. George Fromm, Ph.D., Vice President of Research and Development, Shattuck, and Kyung Jin Yoo, Research Associate, ShattuckSession: Immunology - Combination Immunotherapies 2 Date/Time: Wednesday, April 13, 2022, 9:00 a.m. to 12:30 p.m. ETLocation: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 37Abstract Number: 4214
Additional meeting information can be found on the AACR website, https://www.aacr.org. The posters will be available under the Events & Presentations section of the Company’s website shortly after the event.
About Shattuck Labs, Inc.Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in two Phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid tumors or lymphomas. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor Contact:Conor RichardsonSenior Director, Finance & Investor RelationsShattuck Labs, Inc.InvestorRelations@shattucklabs.com
Media Contact:Stephanie AscherManaging DirectorStern Investor Relations, Inc.Stephanie.ascher@sternir.com
1 Year Shattuck Labs Chart |
1 Month Shattuck Labs Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions